Juno Therapeutics' CAR T Cell Product Candidate JCAR017 Demonstrates Continuing Encouraging Outcomes in Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
Hal Lindon